Changes of cytokine production and cell viability of peripheral blood mononuclear cells from silicosis patients: effect of in vitro treatment with acetylsalicylic acid.
In this study, IL-6 and IL-12p40 production and cell viability of peripheral blood mononuclear cells from silicosis patients after in vitro stimulation were investigated. Furthermore, the effects of introducing acetylsalicylic acid to stimulated patients' peripheral blood mononuclear cells on cytokine production and cell viability were determined. Nine patients with moderate silicosis, 11 with severe silicosis and 14 healthy subjects were recruited for this study. The level of IL-6 produced by patients peripheral blood mononuclear cells decreased depending on the stage of the disease. The addition of acetylsalicylic acid had significantly suppressive effect on the IL-6 production by lipopolysaccharide-stimulated patients' peripheral blood mononuclear cells. Acetylsalicylic acid treatment of C3 binding glycoprotein-stimulated patients' peripheral blood mononuclear cells led to significant upregulation of IL-12p40 production. Results showed a stage-dependent decrease of cell viability of peripheral blood mononuclear cells from silicosis patients. Acetylsalicylic acid significantly decreased cell viability entirely in stimulated peripheral blood mononuclear cells from patients with severe silicosis. In conclusion, this study showed that the disease progression affects peripheral blood mononuclear cells in patients with silicosis and causes functional changes that became apparent after stimulation. Our study demonstrated that in severe silicosis the treatment with acetylsalicylic acid, as an anti-inflammatory agent, might not be beneficial for patients.
Dobreva
Zlatka Georgieva
ZG
Department of Molecular Biology, Immunology & Genetics, Faculty of Medicine, Trakia University, Stara Zagora, Bulgaria. zdobreva@mf.uni-sz.bg
Prakova
Gospodinka Radeva
GR
Slavov
Emil Slavov
ES
Stanilova
Spaska Angelova
SA
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D002470:Cell Survival / Q000187:drug effects; D006801:Humans; D053762:Interleukin-12 Subunit p40 / Q000378:metabolism*; D015850:Interleukin-6 / Q000378:metabolism*; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism*; D012829:Silicosis / Q000188:drug therapy / Q000276:immunology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D053762:Interleukin-12 Subunit p40; D015850:Interleukin-6; D001241:Aspirin